Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2016 - 2025)

Arrowhead Pharmaceuticals' Other Non Operating Income history spans 15 years, with the latest figure at $277000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 18.77% year-over-year to $277000.0; the TTM value through Dec 2025 reached $5.2 million, up 384.19%, while the annual FY2025 figure was $5.3 million, 400.86% up from the prior year.
  • Other Non Operating Income reached $277000.0 in Q4 2025 per ARWR's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.7 million in Q3 2025 to a low of -$3.1 million in Q3 2024.
  • Average Other Non Operating Income over 5 years is $350400.0, with a median of $323500.0 recorded in 2023.
  • The largest YoY upside for Other Non Operating Income was 2262.5% in 2024 against a maximum downside of 534.87% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$707000.0 in 2021, then surged by 171.71% to $507000.0 in 2022, then fell by 16.96% to $421000.0 in 2023, then dropped by 19.0% to $341000.0 in 2024, then dropped by 18.77% to $277000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Other Non Operating Income are $277000.0 (Q4 2025), $4.7 million (Q3 2025), and -$176000.0 (Q2 2025).